These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

654 related items for PubMed ID: 9884276

  • 1. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy.
    Turgeon N, Fishman JA, Basgoz N, Tolkoff-Rubin NE, Doran M, Cosimi AB, Rubin RH.
    Transplantation; 1998 Dec 27; 66(12):1780-6. PubMed ID: 9884276
    [Abstract] [Full Text] [Related]

  • 2. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
    Winston DJ, Busuttil RW.
    Transplantation; 2003 Jan 27; 75(2):229-33. PubMed ID: 12548129
    [Abstract] [Full Text] [Related]

  • 3. Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir.
    Turgeon N, Fishman JA, Doran M, Basgoz N, Tolkoff-Rubin NE, Cosimi AB, Rubin RH.
    Transpl Infect Dis; 2000 Mar 27; 2(1):2-10. PubMed ID: 11429003
    [Abstract] [Full Text] [Related]

  • 4. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
    Flechner SM, Avery RK, Fisher R, Mastroianni BA, Papajcik DA, O'Malley KJ, Goormastic M, Goldfarb DA, Modlin CS, Novick AC.
    Transplantation; 1998 Dec 27; 66(12):1682-8. PubMed ID: 9884259
    [Abstract] [Full Text] [Related]

  • 5. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH, Kemmerly SA, Conti D, Doran M, Murray BM, Neylan JF, Pappas C, Pitts D, Avery R, Pavlakis M, Del Busto R, DeNofrio D, Blumberg EA, Schoenfeld DA, Donohue T, Fisher SA, Fishman JA.
    Transpl Infect Dis; 2000 Sep 27; 2(3):112-7. PubMed ID: 11429021
    [Abstract] [Full Text] [Related]

  • 6. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
    Noble S, Faulds D.
    Drugs; 1998 Jul 27; 56(1):115-46. PubMed ID: 9664203
    [Abstract] [Full Text] [Related]

  • 7. Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients.
    Conti DJ, Freed BM, Singh TP, Gallichio M, Gruber SA, Lempert N.
    Arch Surg; 1995 Nov 27; 130(11):1217-21; discussion 1221-2. PubMed ID: 7487465
    [Abstract] [Full Text] [Related]

  • 8. Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database.
    Badley AD, Seaberg EC, Porayko MK, Wiesner RH, Keating MR, Wilhelm MP, Walker RC, Patel R, Marshall WF, DeBernardi M, Zetterman R, Steers JL, Paya CV.
    Transplantation; 1997 Jul 15; 64(1):66-73. PubMed ID: 9233703
    [Abstract] [Full Text] [Related]

  • 9. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial.
    Hibberd PL, Tolkoff-Rubin NE, Conti D, Stuart F, Thistlethwaite JR, Neylan JF, Snydman DR, Freeman R, Lorber MI, Rubin RH.
    Ann Intern Med; 1995 Jul 01; 123(1):18-26. PubMed ID: 7762909
    [Abstract] [Full Text] [Related]

  • 10. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F, Alberú J, Soto-Ramírez LE, González-Aguirre H, Muñoz Trejo T, Mancilla E, Díliz H, Correa-Rotter R, Sierra-Madero J.
    Rev Invest Clin; 2002 Jul 01; 54(3):198-203. PubMed ID: 12183888
    [Abstract] [Full Text] [Related]

  • 11. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients.
    Martin M, Mañez R, Linden P, Estores D, Torre-Cisneros J, Kusne S, Ondick L, Ptachcinski R, Irish W, Kisor D.
    Transplantation; 1994 Oct 15; 58(7):779-85. PubMed ID: 7940710
    [Abstract] [Full Text] [Related]

  • 12. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial.
    Singh N, Yu VL, Mieles L, Wagener MM, Miner RC, Gayowski T.
    Ann Intern Med; 1994 Mar 01; 120(5):375-81. PubMed ID: 8304654
    [Abstract] [Full Text] [Related]

  • 13. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients.
    Winston DJ, Wirin D, Shaked A, Busuttil RW.
    Lancet; 1995 Jul 08; 346(8967):69-74. PubMed ID: 7603215
    [Abstract] [Full Text] [Related]

  • 14. Eradication of cytomegalovirus reactivation disease using high-dose acyclovir and targeted intravenous ganciclovir in kidney and kidney/pancreas transplantation.
    Shen GK, Alfrey EJ, Knoppel CL, Dafoe DC, Scandling JD.
    Transplantation; 1997 Sep 27; 64(6):931-3. PubMed ID: 9326425
    [Abstract] [Full Text] [Related]

  • 15. Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients.
    McKeen JT, Tsapepas DS, Li H, Anamisis A, Martin ST.
    Prog Transplant; 2015 Mar 27; 25(1):39-44. PubMed ID: 25758799
    [Abstract] [Full Text] [Related]

  • 16. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
    Gotti E, Suter F, Baruzzo S, Perani V, Moioli F, Remuzzi G.
    Clin Transplant; 1996 Dec 27; 10(6 Pt 1):550-5. PubMed ID: 8996777
    [Abstract] [Full Text] [Related]

  • 17. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance.
    van der Beek MT, Berger SP, Vossen AC, van der Blij-de Brouwer CS, Press RR, de Fijter JW, Claas EC, Kroes AC.
    Transplantation; 2010 Feb 15; 89(3):320-6. PubMed ID: 20145523
    [Abstract] [Full Text] [Related]

  • 18. Preemptive therapy for the prevention of cytomegalovirus disease in renal transplant recipients: our preliminary experience.
    Paudice N, Mehmetaj A, Zanazzi M, Moscarelli L, Piperno R, Di Maria L, Bertoni E, Salvadori M.
    Transplant Proc; 2009 May 15; 41(4):1204-6. PubMed ID: 19460517
    [Abstract] [Full Text] [Related]

  • 19. Failure of ganciclovir prophylaxis to completely eradicate CMV disease in renal transplant recipients treated with intense anti-rejection immunotherapy.
    Isenberg AL, Shen GK, Singh TP, Hahn A, Conti DJ.
    Clin Transplant; 2000 Jun 15; 14(3):193-8. PubMed ID: 10831076
    [Abstract] [Full Text] [Related]

  • 20. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
    Said T, Nampoory MR, Johny KV, Pacsa AS, Mini Abraham P, Nair MP, Abdel-Haleem M, Samhan M, Al-Mousawi M.
    Transplant Proc; 2004 Jun 15; 36(6):1847-9. PubMed ID: 15350495
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.